Obesity Medications: What Research Shows About GLP-1 Drugs and Health Equity

The development and FDA approval of glucagon-like peptide-1 receptor agonist medications for chronic weight management has transformed the clinical landscape for obesity treatment and generated intense public, scientific, and policy attention. Medications including semaglutide marketed as Wegovy and tirzepatide marketed as Zepbound have demonstrated weight loss of 15 to 22 percent of body weight in clinical trials, outcomes that were previously achievable only through bariatric surgery. Research on the long-term effects of these medications, their mechanisms, their risks, and the equity implications of their cost and access is rapidly developing. GLP-1 receptor agonists work by mimicking naturally occurring hormones that regulate appetite, slow gastric emptying, and produce satiety signals that reduce food intake. The SELECT trial, which studied semaglutide in individuals with obesity and established cardiovascular disease without diabetes, found significant reductions in major cardiovascular events including heart attacks and stroke, establishing a cardiovascular benefit beyond weight loss alone. This finding positions GLP-1 agonists as potentially important treatments not just for weight management but for cardiovascular risk reduction in a large population. Long-term outcome data is still developing for the newest and highest-efficacy formulations. Clinical trials demonstrating weight loss efficacy have ranged from one to two years in duration, leaving questions about what happens over longer periods, whether weight is maintained after stopping medication, and what the full long-term safety profile looks like. Research on earlier GLP-1 agonists, which have been used for diabetes treatment for longer periods, provides some reassurance about long-term safety, but the newer high-dose formulations are different enough that extrapolation is limited. Weight regain following medication discontinuation is a documented concern. Research finds that substantial weight regain occurs when patients stop taking GLP-1 agonists, confirming that these medications require long-term or indefinite use to maintain their effects, which has implications for cost, side effects, and patient commitment. This pattern reflects the underlying biology of obesity, in which compensatory mechanisms resist weight loss and require ongoing treatment to maintain reduced weight. Cost and insurance coverage represent the most significant barriers to access. GLP-1 agonists for weight management are priced at approximately one thousand dollars per month or more without insurance coverage, placing them out of reach for most patients without substantial third-party payment. Medicare was explicitly prohibited from covering weight loss medications until legislation expanded coverage in recent years, and even with Medicare coverage, cost-sharing requirements and formulary restrictions limit access. Medicaid coverage varies significantly by state, with most states not covering these medications for weight management. Research on the health equity implications of GLP-1 agonist access finds that the populations with the highest burden of obesity-related disease, including Black and Latino Americans, low-income Americans, and rural Americans, have the least access to these medications. If the medications remain priced out of reach for these populations while accessible to higher-income patients, they could widen existing health disparities rather than narrowing them. Research on disparities in prescription rates finds that GLP-1 agonist use for weight management is significantly lower among Black and Latino patients than white patients even after controlling for insurance status, reflecting both provider prescribing disparities and patient uptake differences. Generic competition, patent expiration, and potential manufacture-at-scale cost reductions could dramatically change the access landscape over the next decade. Research on drug pricing dynamics suggests that generic entry typically reduces prices substantially, and if GLP-1 agonist manufacturing costs decline with scale, the medications could become accessible to a much larger proportion of the population. Policy interventions including expanded insurance coverage mandates, negotiation of prices for Medicare, and international comparison pricing are options that could improve access in the nearer term. The medications' potential to reduce obesity-related comorbidities including type 2 diabetes, cardiovascular disease, sleep apnea, and joint disease at population scale is a significant public health opportunity that researchers and policymakers are examining. Economic analyses of population-wide GLP-1 agonist use for high-risk individuals find that the reductions in disease burden and healthcare utilization could potentially offset a substantial share of medication costs, supporting arguments for broader insurance coverage on both health and economic grounds.